# Unique Pharmaceutical Laboratories

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/unique-pharmaceutical-laboratories
Canonical HTML page: https://getbiobrief.com/entity/unique-pharmaceutical-laboratories

## Timeline

- **2026-07-21**: FDA Recall Notice Published — The U.S. FDA releases a public notice detailing the voluntary recall, classifies it as Class III, and confirms that no adverse incidents have been reported. Distributor Rising Pharma begins customer outreach for returns.
- **2025-09-19**: Voluntary Recall Initiated — Unique Pharmaceutical Laboratories initiates a voluntary recall of four lots of cetirizine hydrochloride tablets after discovering misprinted tablet identifiers indicating potential cross-contamination with another medication.

## Recent coverage (1 stories)

### 4 Lots of Generic Zyrtec Recalled Over Cross-Contamination Risk
2026-07-21 19:07:43 · Sentiment: Bearish · Impact: 6/10 · Sources: 4

J.B. Chemicals unit Unique Pharmaceutical Laboratories recalls four lots of over-the-counter cetirizine following FDA notice of potential cross-contamination. Though labeled Class III, the error highlights persistent quality-control challenges in the global generic supply chain.
Full story: https://getbiobrief.com/story/cetirizine-recall-jb-chemicals-cross-contamination

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.